-
Competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 35-37 weeks' gestation.
Andrietti S, Silva M, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;48:72-9. pdf -
Maternal serum PAPP-A and free beta-hCG at 12, 22 and 32 weeks' gestation in screening for pre-eclampsia.
Wright A, Guerra L, Pellegrino M, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:762-7. pdf -
Maternal serum soluble fms-like tyrosine kinase-1 at 22 and 32 weeks in the prediction of pre-eclampsia.
Wright D, Krajewska K, Bogdanova A, Wright A, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:755-61. pdf -
Mean arterial pressure at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia.
Tayyar A, Krithinakis K, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:573-9. pdf -
Uterine artery pulsatility index at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia.
O'Gorman N, Tampakoudis G, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:565-72. pdf -
Maternal serum soluble fms-like tyrosine kinase-1 at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia.
Tsiakkas A, Mendez O, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:478-83. pdf -
Maternal serum placental growth factor at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia.
Tsiakkas A, Cazacu R, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:472-7. pdf -
Maternal serum alpha-fetoprotein at 12, 22 and 32 weeks' gestation in screening for pre-eclampsia.
Bredaki FE, Mataliotakis M, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:466-71. pdf -
Uterine artery pulsatility index at 30-34 weeks' gestation in the prediction of adverse perinatal outcome.
Valiño N, Giunta G, Gallo DM, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:308-15. pdf -
Biophysical and biochemical markers at 35-37 weeks' gestation in the prediction of adverse perinatal outcome.
Valiño N, Giunta G, Gallo DM, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:203-9. pdf -
Biophysical and biochemical markers at 30-34 weeks' gestation in the prediction of adverse perinatal outcome.
Valino N, Giunta G, Gallo DM, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:194-202. pdf -
Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30-34 weeks' gestation.
Tsiakkas A, Saiid Y, Wright A, Wright D, Nicolaides KH.
Am J Obstet Gynecol 2016;215:87.e1-87.e17. pdf -
Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19-24 weeks' gestation.
Gallo DM, Wright D, Casanova C, Campanero M, Nicolaides KH.
Am J Obstet Gynecol 2016;214:619.e1-619.e17. pdf -
Some thoughts on the true value of ultrasound.
Nicolaides KH.
Ultrasound Obstet Gynecol 2007;30:671-4. -
Endothelial nitric oxide synthase gene polymorphism (Glu298Asp) and development of pre-eclampsia: a case-control study and a meta-analysis.
Yu CKh, Casas JP, Savvidou MD, Sahemey MK, Nicolaides KH, Hingorani AD.
BMC Pregnancy Childbirth 2006;6:7. -
Prediction of pre-eclampsia by uterine artery Doppler ultrasonography and maternal serum pregnancy-associated plasma protein-A, free beta-human chorionic gonadotropin, activin A and inhibin A at 22 + 0 to 24 + 6 weeks' gestation.
Spencer K, Yu CK, Savvidou M, Papageorghiou AT, Nicolaides KH.
Ultrasound Obstet Gynecol 2006;27:658-63. -
Can aneroid sphygmomanometers be used at altitude?
Kametas NA, McAuliffe F, Krampl E, Nicolaides KH, Shennan AH.
J Hum Hypertens 2006;20:517-22.